Navigating the future of product development

Cornell Tech experts Keith Cowing and Josh Hartmann offer a preview of the 2024 Product and Tech Leadership Summit.

Around Cornell

Blockchains kill in Cornell Tech professor’s thriller novel

A confluence of events, combined with a healthy obsession for details and a love of writing, gave Cornell Tech computer scientist Ari Juels just what he needed to produce his second fiction thriller, “The Oracle.”

Vaccine shows promise against CMV, a virus that causes birth defects

An experimental mRNA vaccine against human cytomegalovirus, a common virus that can infect babies during pregnancy, elicited some of the most promising immune responses to date of any vaccine candidate, according to a study by Weill Cornell Medicine investigators.

Apixaban no better than aspirin for preventing some strokes

A multicenter, phase 3 clinical trial has found that apixaban is no more effective than aspirin at preventing a second stroke in patients diagnosed with a milder, related condition called atrial cardiopathy, according to new research.

NIH grant awarded for study of key membrane proteins

Alessio Accardi, professor of physiology and biophysics in anesthesiology at Weill Cornell Medicine, has been awarded a five-year, $2.7 million grant for fundamental research on cell membrane proteins that have critical roles in biology and are involved in numerous human diseases.

NIH grant explores repetitive DNA sequences

Jeannine Gerhardt, an assistant professor of stem cell biology in obstetrics and gynecology and in reproductive medicine at Weill Cornell Medicine, has received a five-year, $2.1 million grant for the study of repetitive DNA and RNA sequences and the mechanisms by which they cause cell dysfunction and diseases.

Entrepreneurs share tips on working with social media influencers

A panel of Cornell alumni and other marketing executives explored the important role social influencers play in business today during a Jan. 18 event.

Around Cornell

Structural study points the way to better malaria drugs

Structural insights into a potent antimalarial drug candidate’s interaction with a malaria parasite have paved the way for drug-resistant malaria therapies, according to a new study by researchers at Weill Cornell Medicine and Van Andel Institute.

VillageMD CEO named Cornell Entrepreneur of the Year 2024

Tim Barry ’93 co-founded a health care company that offers primary care, multispecialty and urgent care options to 1.6 million patients throughout the U.S.